$NGENF News
Last published 9mo ago
- 9mo agoNGENNGENFNervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy SymposiumGlobeNewswireAdam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of
- 9mo agoNGENNGENFNervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord InjuryGlobeNewswireVANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class
- 10mo agoNGENFNGENNervGen Pharma Begins Trading on Nasdaq TodayGlobeNewswireVANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class
- 1y agoNGENFNervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord InjuryGlobeNewswireStudy met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals
- 1y agoNGENFNervGen Pharma to Host Virtual Investor EventGlobeNewswireVANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (TSXV:NGEN) (OTCQB:NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced
- 4y agoNGENFTSXV:NGENNervGen Pharma's NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve UniversityBusiness WireThe independent peer-reviewed study showed improved memory as well as motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke onset There is currently no FDA-approved drug for the repair of damage from a stro
- 4y agoNGENFTSXV:NGENNervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & RehabilitationBusiness WirePhase 1b/2a trial of NervGen's lead compound, NVG-291, is based upon unprecedented, peer-reviewed animal studies demonstrating pronounced functional recovery from spinal cord injury "The ability of NVG-291 to demonstrate meaningful recovery in